VIDEO: Evolutions in HER2-targeted therapies for breast cancer
Click Here to Manage Email Alerts
In this video, Debu Tripathy, MD, discussed developments in HER2-positive breast cancer targeted treatments, including antibody-drug conjugates, which were reviewed at 39th Miami Breast Cancer Conference.
"This is a field that has moved very quickly," Tripathy, professor of medicine and chair, department of breast medical oncology at The University of Texas MD Anderson Cancer Center, said in his discussion of antibody-drug conjugates such as trastuzumab deruxtecan.
"[Trastuzumab deruxtecan] has been blowing the socks off of other drugs, and the results of the DESTINY-03 Trial, which was a second-line study comparing TDM1 to trastuzumab deruxtecan, showed a clear improvement in outcome," Tripathy said.
Collapse
Read more about
Click Here to Manage Email Alerts